my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-08-2012: Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a number of lead compounds against a panel of X-MAN™ isogenic disease model human cell lines, which accurately model the mutations found in cancer cells.
Profiling of Domainex’s lead TBK1/IKKe dual inhibitor molecules against the X-MAN cell lines will enable identification of the effect of individual mutations on drug activity and resistance and prediction of which patient sub-groups will respond. This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.
Financial terms of the agreement are not disclosed.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program
Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a n ... more
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
UCB and Domainex Ltd have jointly published the results of a collaboration in the field of cancer drug discovery. Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known ... more
Domainex to Invest in its Drug Discovery Services and Internal Oncology Pipeline in 2011
Domainex Ltd has announced plans to significantly expand its medicinal chemistry and biology capabilities in 2011. The expansion will involve relocation to larger laboratories in Cambridge and investment in new technologies that will enhance its current service offering. This will allow Dom ... more
Domainex uses unique and proprietary technologies to resolve common bottlenecks facing the pharmaceutical and biotechnology industries in the post-genomic era. Major discovery 'gaps' exist between the vast amount of genomic information that is now available, the accessibility of the corresp ... more
Horizon and Boehringer Ingelheim enter oncology research service collaboration
Horizon Discovery Ltd announced it has signed a research service collaboration agreement with Boehringer Ingelheim. Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimiza ... more
Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program
Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a n ... more
Horizon Discovery Appoints Richard Vellacott as Chief Financial Officer
Horizon Discovery Limited has announced the appointment of Mr. Richard Vellacott as Chief Financial Officer. Richard has over 15 years’ experience in working with life science companies, from start-ups to global pharmaceuticals, and is a chartered accountant with a first class degree in Bio ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
